Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
Animals
Biomarkers
/ blood
Brain
/ metabolism
Cerebrovascular Circulation
Diagnostic Imaging
/ methods
Disease Management
Disease Susceptibility
Dopamine
/ metabolism
Energy Metabolism
Fluorodeoxyglucose F18
Gene Expression Regulation
Genetic Predisposition to Disease
Humans
Magnetic Resonance Imaging
Multimodal Imaging
Neurotransmitter Agents
/ metabolism
Parkinson Disease
/ blood
Positron-Emission Tomography
Prodromal Symptoms
Severity of Illness Index
18F-FDG PET
Biomarkers
Brain networks
Idiopathic REM sleep behavior disorder
Neuro-imaging
Parkinson’s disease
fMRI
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
22
02
2021
accepted:
02
06
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
21
1
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) commences several years before the onset of motor features. Pathophysiological understanding of the pre-clinical or early prodromal stages of PD are essential for the development of new therapeutic strategies. Two categories of patients are ideal to study the early disease stages. Idiopathic rapid eye movement sleep behavior disorder (iRBD) represents a well-known prodromal stage of PD in which pathology is presumed to have reached the lower brainstem. The majority of patients with iRBD will develop manifest PD within years to decades. Another category encompasses non-manifest mutation carriers, i.e. subjects without symptoms, but with a known mutation or genetic variant which gives an increased risk of developing PD. The speed of progression from preclinical or prodromal to full clinical stages varies among patients and cannot be reliably predicted on the individual level. Clinical trials will require inclusion of patients with a predictable conversion within a limited time window. Biomarkers are necessary that can confirm pre-motor PD status and can provide information regarding lead time and speed of progression. Neuroimaging changes occur early in the disease process and may provide such a biomarker. Studies have focused on radiotracer imaging of the dopaminergic nigrostriatal system, which can be assessed with dopamine transporter (DAT) single photon emission computed tomography (SPECT). Loss of DAT binding represents an effect of irreversible structural damage to the nigrostriatal system. This marker can be used to monitor disease progression and identify individuals at specific risk for phenoconversion. However, it is known that changes in neuronal activity precede structural changes. Functional neuro-imaging techniques, such as
Identifiants
pubmed: 34530732
doi: 10.1186/s10020-021-00327-x
pii: 10.1186/s10020-021-00327-x
pmc: PMC8447708
doi:
Substances chimiques
Biomarkers
0
Neurotransmitter Agents
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Informations de copyright
© 2021. The Author(s).
Références
Arch Neurol. 2005 Mar;62(3):378-82
pubmed: 15767502
Neurology. 2014 Nov 25;83(22):2046-53
pubmed: 25355821
Mov Disord. 2021 Aug;36(8):1889-1898
pubmed: 33788284
Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):437-450
pubmed: 31768600
Acta Neurol Belg. 2020 Dec;120(6):1297-1305
pubmed: 32813147
Curr Opin Neurol. 2013 Dec;26(6):662-70
pubmed: 24150222
Brain. 2020 Oct 1;143(10):3077-3088
pubmed: 32830221
J Parkinsons Dis. 2019;9(s2):S281-S295
pubmed: 31498132
Sleep. 2013 Dec 01;36(12):1885-92
pubmed: 24293763
Neurology. 2015 Jan 27;84(4):399-406
pubmed: 25540317
Parkinsonism Relat Disord. 2019 Jul;64:97-105
pubmed: 30930059
Mov Disord. 2021 Jan;36(1):230-235
pubmed: 32909650
Curr Neurol Neurosci Rep. 2017 Apr;17(4):34
pubmed: 28324303
Parkinsonism Relat Disord. 2020 Dec;81:113-122
pubmed: 33120072
Neurosci Bull. 2014 Oct;30(5):823-37
pubmed: 25260798
Eur J Neurol. 2020 Jul;27(7):1285-1295
pubmed: 32170820
Cereb Cortex. 2020 May 14;30(5):2867-2878
pubmed: 31813991
Sleep Med Rev. 2018 Oct;41:266-274
pubmed: 29784534
Neuroimage Clin. 2017 Aug 02;16:313-318
pubmed: 28856094
J Clin Neurol. 2019 Apr;15(2):175-183
pubmed: 30877691
Mov Disord. 2012 Jan;27(1):54-60
pubmed: 22252891
Int Rev Neurobiol. 2018;142:177-223
pubmed: 30409253
Brain. 2014 Dec;137(Pt 12):3122-8
pubmed: 25338949
Mov Disord. 2017 Oct;32(10):1482-1486
pubmed: 28734065
Brain. 2013 Aug;136(Pt 8):2419-31
pubmed: 23884810
Neuroimage. 2009 Apr 1;45(2):260-6
pubmed: 18992824
J Parkinsons Dis. 2020;10(4):1737-1749
pubmed: 32925097
Curr Opin Neurobiol. 2006 Dec;16(6):629-37
pubmed: 17084615
Ann Neurol. 2012 Nov;72(5):635-47
pubmed: 22941893
Neurology. 2014 Feb 18;82(7):620-7
pubmed: 24453082
Brain. 1997 Aug;120 ( Pt 8):1315-24
pubmed: 9278625
Lancet Neurol. 2013 May;12(5):443-53
pubmed: 23562390
Mov Disord. 2012 May;27(6):720-6
pubmed: 22322798
J Neurosci. 2010 Jan 20;30(3):1049-56
pubmed: 20089913
Brain. 2016 Aug;139(Pt 8):2224-34
pubmed: 27297241
J Nucl Med. 2018 Sep;59(9):1437-1444
pubmed: 29476004
Eur J Neurol. 2020 Apr;27(4):644-652
pubmed: 31725927
Neurology. 2017 Aug 1;89(5):439-444
pubmed: 28679601
Sleep. 2006 Jul;29(7):927-33
pubmed: 16895260
Philos Trans R Soc Lond B Biol Sci. 2016 Oct 5;371(1705):
pubmed: 27574302
JAMA Neurol. 2016 Oct 1;73(10):1217-1224
pubmed: 27571329
Lancet Neurol. 2018 Jul;17(7):618-628
pubmed: 29866443
Int Rev Neurobiol. 2018;142:261-287
pubmed: 30409255
Brain. 2008 May;131(Pt 5):1373-80
pubmed: 18400841
Proc Natl Acad Sci U S A. 1986 Feb;83(4):1140-4
pubmed: 3485282
PLoS One. 2014 Feb 26;9(2):e89741
pubmed: 24587002
Science. 1988 Jul 22;241(4864):462-4
pubmed: 3260686
Sleep Med. 2020 May;69:198-203
pubmed: 32135454
J Neurol. 2019 Jan;266(1):1-26
pubmed: 29761296
Hum Brain Mapp. 2015 Sep;36(9):3575-85
pubmed: 26037537
Sleep Med. 2019 Jun;58:35-41
pubmed: 31078078
J Sleep Res. 2021 Jun;30(3):e13136
pubmed: 32608031
J Cereb Blood Flow Metab. 2015 Dec;35(12):2062-9
pubmed: 26219593
Clin Neurophysiol. 2007 Nov;118(11):2317-31
pubmed: 17900977
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Lancet Neurol. 2009 Dec;8(12):1128-39
pubmed: 19909911
Neuroimage Clin. 2020;25:102138
pubmed: 31911344
Neuroimage. 2014 Jan 15;85 Pt 2:637-47
pubmed: 23711535
J Nucl Med. 1995 Jul;36(7):1238-48
pubmed: 7790950
Mov Disord. 2020 Dec;35(12):2201-2210
pubmed: 32853481
Parkinsonism Relat Disord. 2020 Jun;75:63-69
pubmed: 32480309
Cereb Cortex. 2018 Dec 1;28(12):4121-4135
pubmed: 29088324
Mov Disord. 2016 Dec;31(12):1820-1828
pubmed: 27653520
Hum Brain Mapp. 2019 Jun 1;40(8):2546-2555
pubmed: 30793410
Ann N Y Acad Sci. 2003 Jun;991:199-213
pubmed: 12846988
Int Rev Neurobiol. 2018;142:225-260
pubmed: 30409254
Geriatr Gerontol Int. 2014 Jan;14(1):115-20
pubmed: 23586530
Sleep Med. 2013 Aug;14(8):744-8
pubmed: 23347909
Lancet Neurol. 2018 Jul;17(7):629-640
pubmed: 29914708
J Neurosci. 2016 Jul 6;36(27):7128-41
pubmed: 27383589
Neurology. 2009 Apr 14;72(15):1296-300
pubmed: 19109537
Psychogeriatrics. 2010 Sep;10(3):144-52
pubmed: 20860570
Nat Rev Neurosci. 2007 Sep;8(9):700-11
pubmed: 17704812
Trends Neurosci. 2009 Oct;32(10):548-57
pubmed: 19765835
Circ Res. 1979 Jan;44(1):127-37
pubmed: 363301
Arch Neurol. 2007 Jan;64(1):20-4
pubmed: 17210805
J Cereb Blood Flow Metab. 2020 Mar;40(3):552-562
pubmed: 30741074
Neurology. 2006 Nov 14;67(9):1618-22
pubmed: 17101893
Mov Disord. 2018 Oct;33(10):1643-1646
pubmed: 30145841
Brain. 2007 Jul;130(Pt 7):1834-46
pubmed: 17470495
Mov Disord. 2020 Aug;35(8):1475-1481
pubmed: 32459015
Neurology. 2012 Dec 11;79(24):2302-6
pubmed: 23115214
JAMA Neurol. 2018 Mar 1;75(3):312-319
pubmed: 29309488
Annu Rev Neurosci. 1986;9:357-81
pubmed: 3085570
J Neurol Sci. 2013 Nov 15;334(1-2):48-54
pubmed: 23927939
Eur J Neurol. 2011 May;18(5):784-8
pubmed: 21143707
Mov Disord. 2019 Oct;34(10):1464-1470
pubmed: 31412427
Mov Disord. 2011 Aug 1;26(9):1717-24
pubmed: 21542022
Ann Neurol. 2017 Sep;82(3):419-428
pubmed: 28833467